SCHEMBL9129451

SCHEMBL9129451

CNCC(c1ccccc1)c1cccnc1

nearest known ligand 0.53

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
SLC6A3 Q01959 6/20 0.53
SLC6A2 P23975 5/20 0.53
SLC6A4 P31645 5/20 0.53
CFTR P13569 2/20 0.53
GOPC Q9HD26 2/20 0.53
KDM4E B2RXH2 1/20 0.51
KCNH2 Q12809 5/20 0.51
CYP3A4 P08684 5/20 0.51
CYP2D6 P10635 5/20 0.51
SMN1; SMN2 Q16637 1/20 0.50
TBXAS1 P24557 1/20 0.48
KCNA5 P22460 3/20 0.47
TAAR1 Q96RJ0 1/20 0.47
HTR2A P28223 1/20 0.44
HRH1 P35367 1/20 0.44
CYP1A2 P05177 1/20 0.44
CYP2C9 P11712 1/20 0.44
CYP2C19 P33261 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1908636 0.82 TAAR1 (0.64) SLC6A3SLC6A2SLC6A4KDM4EKCNH2
SCHEMBL1944201 0.79 CFTR (0.59) SLC6A3SLC6A2SLC6A4CFTRGOPC
SCHEMBL4048311 0.79 SLC6A3 (0.55) SLC6A3SLC6A2SLC6A4KDM4EKCNH2
SCHEMBL13675427 0.79 KDM4E (0.51) SLC6A3SLC6A2SLC6A4CFTRGOPC
SCHEMBL6320255 0.79 SLC6A3 (0.55) SLC6A3SLC6A2SLC6A4KDM4EKCNH2
Ammonia Solution, Strong SCHEMBL5999698 0.78 CFTR (0.57) SLC6A3SLC6A2SLC6A4CFTRGOPC
Hydrochloric Acid SCHEMBL14126604 0.77 HIF1A (0.54) SLC6A3SLC6A2SLC6A4KDM4EKCNH2
Bromide SCHEMBL6286509 0.77 SLC6A3 (0.53) SLC6A3SLC6A2SLC6A4KDM4EKCNH2
SCHEMBL7506738 0.77 SLC6A2 (0.47) SLC6A3SLC6A2SLC6A4CFTRGOPC
SCHEMBL23970158 0.76 TBXAS1 (0.56) SLC6A3SLC6A2SLC6A4CFTRGOPC

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2948135-A1 COMPOSITIONS AND METHODS FOR THE TREATMENT OF PERVASIVE DEVELOPMENT DISORDERS Case Western Reserve University (US) 2015-12-02 EP disclosed
US-20140271662-A1 PYRAZOLE DERIVATIVES AS PROTEIN KINASE MODULATORS ASTEX THERAPEUTICS LTD (GB) 2014-09-18 US disclosed
US-20140271662-A1 PYRAZOLE DERIVATIVES AS PROTEIN KINASE MODULATORS ASTEX THERAPEUTICS LTD (GB) 2014-09-18 US disclosed
WO-2014117089-A1 COMPOSITIONS AND METHODS FOR THE TREATMENT OF PERVASIVE DEVELOPMENT DISORDERS CASE WESTERN RESERVE UNIVERSITY (US) 2014-07-31 WO disclosed
US-20130005702-A1 PYRAZOLE DERIVATIVES AS PROTEIN KINASE MODULATORS ASTEX THERAPEUTICS LIMITED (GB) 2013-01-03 US disclosed
US-20130005702-A1 PYRAZOLE DERIVATIVES AS PROTEIN KINASE MODULATORS ASTEX THERAPEUTICS LIMITED (GB) 2013-01-03 US disclosed
US-5430044-A Arylalkyl-amines and -amides having anticonvulsant and neuroprotective properties FISONS CORPORATION (GB) 1995-07-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130005702-A1 PYRAZOLE DERIVATIVES AS PROTEIN KINASE MODULATORS PRKCB, MAP3K19, MAP4K2 SLC6A3 4765/4885SLC6A2 4834/4885SLC6A4 4737/4885
US-20140271662-A1 PYRAZOLE DERIVATIVES AS PROTEIN KINASE MODULATORS GRK3, GRK2, NR0B2 SLC6A3 3932/4885SLC6A2 4587/4885SLC6A4 4440/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.